AXL Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
AXL Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy was generated using PatSnap Life Sciences MCP Servers. Target & Disease MCP contributed the biology and disease context, while Clinical Trials MCP contributed validation evidence and clinical competition signals.
Why this report exists: it shows how AI agents can use PatSnap MCP data to produce target evaluation workflows covering biology, validation, competition, IP, and R&D recommendation. Explore PatSnap Life Sciences MCP Servers for AI agents.
Executive Summary
This AXL Target Evaluation Report is generated from PatSnap MCP data. AXL is a highly active NSCLC resistance and tumor-microenvironment target, but mixed clinical outcomes mean differentiation and patient selection matter more than target popularity.
Target
AXL
UniProt P30530
Drug Count
151
119 development-stage assets
Trials
86
AXL NSCLC trials retrieved by Clinical Trials MCP
Results
83
Clinical Trials MCP result records
Target Attractiveness Snapshot
Biology
Target & Disease MCP describes AXL as a GAS6-binding receptor tyrosine kinase activating PI3K/AKT, GRB2, PLCG1, LCK, PTPN11 and innate-immune regulatory programs.
Disease Context
In NSCLC, AXL is linked to EMT, EGFR or ALK resistance, immune escape, and multi-kinase combination strategies.
Strategy
Prioritize resistant molecular subgroups and avoid broad AXL claims without biomarkers.
Overall Target Evaluation Score: 76/100
- Biology: AXL biology is broad across survival, migration, immune modulation and resistance.
- Clinical validation: Clinical Trials MCP returned 86 NSCLC trials and 83 result records.
- Competition: Competition is crowded and includes negative Phase 3 experience.
- White space: White space depends on biomarker-led resistance niches.
Biology and Disease Rationale
AXL transduces extracellular GAS6 signals into survival, proliferation, migration and differentiation programs. Target & Disease MCP connects AXL activation to PI3K/AKT signaling and TLR-mediated innate immune inhibition, both relevant for tumor resistance and immune evasion.
Clinical Trials MCP returned ONO-7475 plus osimertinib in EGFR-mutant NSCLC, bemcentinib combinations, gilteritinib in ALK-positive NSCLC, and famitinib/adebrelimab strategies. Result records include ONO-7475 plus osimertinib and SAFFRON-301 with sitravatinib plus tislelizumab.
Explore PatSnap Life Sciences MCP Servers for AI agents
Validation and Clinical Competition
| EGFR-resistance signal | ONO-7475 plus osimertinib in EGFR-mutant advanced NSCLC was indexed as positive Phase 1 evidence. |
| Negative pivotal caution | SAFFRON-301 sitravatinib plus tislelizumab was indexed as a negative Phase 3 result. |
| IO-combination exploration | Bemcentinib plus pembrolizumab/carboplatin/pemetrexed was tested in untreated non-squamous NSCLC with or without STK11 mutation. |
| Kinase overlap | Cabozantinib and sitravatinib records illustrate that AXL is often targeted in multi-kinase packages. |
IP and Competitive Strategy
AXL IP review should compare selective AXL inhibitors, multi-kinase inhibitors, GAS6/AXL biology, EGFR and ALK resistance combinations, STK11 or EMT biomarkers, and IO-combination claims.
Recommendation
AXL remains attractive in NSCLC resistance biology, but the R&D bar is high. New programs should be biomarker-driven and learn directly from negative broad-combination studies.
Bottom line: This AXL Target Evaluation Report is generated from PatSnap MCP data. AXL is a highly active NSCLC resistance and tumor-microenvironment target, but mixed clinical outcomes mean differentiation and patient selection matter more than target popularity.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
